Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2026-03-26 @ 3:15 PM
Ignite Modification Date:
2026-03-26 @ 3:15 PM
NCT ID:
NCT07312292
Brief Summary:
This clinical trial will test whether a short infusion of a drug called angiotensin II can make a liver cancer treatment work better. The drug is given directly into the artery that supplies blood to the liver, right before a treatment called yttrium-90 (90Y) radioembolization.
The main questions it aims to answer are:
* Does angiotensin II help more of the radioactive beads reach the tumor and less reach the healthy parts of the liver?
* Is it safe to add angiotensin II to the standard radioembolization treatment? What will participants do?
* First visit (work-up): Participants will have the standard preparation for radioembolization. A small test dose of radioactive tracer (99mTc-MAA) will be injected into the liver through an artery. On the same day, a SPECT/CT scan will be performed to see how the tracer distributes in the liver and if there are depositions outside the liver. If everything looks good, the participant will return for treatment in 2-3 weeks.
* Second visit (treatment): Participants will receive the actual radioembolization treatment. At each injection site in the liver, first angiotensin II is administered, immediately followed by the injection of the radioactive beads (90Y microspheres). If the treatment requires injections in multiple locations, the participant will receive angiotensin II at each spot.
* After treatment: Participants will receive a PET/CT scan so the research team can see where the radioactive beads went. This will be compared to the distribution of the radioactive tracer (99mTc-MAA) from the first SPECT/CT scan (performed without angiotensin II) to measure how much angiotensin II helped target the tumor.
All monitoring (including blood pressure, heart rate, oxygen saturation, and breathing rate) takes place during the procedure as part of routine care, and there are no extra hospital visits beyond what is normally required for radioembolization.
Study:
NCT07312292
Study Brief:
Protocol Section:
NCT07312292